Merck, as it prepares a new version of its cancer blockbuster Keytruda, gets a boost in its patent dispute with Halozyme ...

When journalist Jon Gluck learned he had multiple myeloma, doctors told him he had 18 months to live. That was 20 years ago. ...

At the crossroads of innovation and equity, Josette Gbemudu and Merck are helping rewrite the narrative for breast cancer ...

Tango Therapeutics rebounds with a stronger pipeline, renewed focus on PRMT5 inhibitors, and key data ahead despite past ...

Healthcare companies are navigating a challenging environment as policy uncertainty and competitive pressures weigh on the ...

US drug companies are increasingly licensing experimental medicines invented by Chinese firms. The recent deals could be ...

BMY teams with BioNTech on BNT327, a dual-target cancer therapy, as legacy drugs face mounting generic pressure ...

Bristol-Myers Squibb and BioNTech announced a major deal worth up to $11 billion in early June. Click here to find out why I ...

With U.S. stocks booming, North American wealthy led the way globally. And the top 1% of wealthy globally—the so-called ...

CURE spoke with the principal investigator of a clinical trial evaluating a therapeutic vaccine for patients with advanced ...

The fraught discussions playing out between President Donald Trump and one of the world’s most powerful figures could shape ...

Byron Allen dials out, Salesforce logs in. Here are the various deal announcements of the past week plus bankruptcy updates.